替诺福韦艾拉酚胺预防围产期乙型肝炎传播:多中心前瞻性观察研究
TAF母婴安全性良好,婴儿7月龄HBsAg阳性率为0%。
要点
- TAF孕期耐受性良好,最常见母体不良事件为恶心(19.0%)。
- 两组均无婴儿出生缺陷,TAF组婴儿体格和神经发育与TDF组相当。
- 所有233名婴儿7月龄HBsAg阳性率为0%。
核心结论
- TAF抗病毒预防对母婴总体安全,并将母婴传播率降至0%。
主要发现
- TAF组平均治疗11.0周,耐受良好,最常见母体不良事件为恶心(19.0%)。
- TAF组分娩时、产后3月、产后6月ALT异常母体分别为1例(0.9%)、3例(2.6%)、9例(7.8%)。
- TDF组安全性与TAF组相当,两组均无婴儿出生缺陷。
- TAF组婴儿出生时和7月龄体格及神经发育与TDF组相当。
- 全部233名婴儿7月龄HBsAg阳性率为0%。
临床怎么用
- 婴儿应接受免疫预防,并随访至7月龄评估HBsAg。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few safety and effectiveness results have been published regarding the administration of tenofovir alafenamide fumarate (TAF) during pregnancy for the prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV). METHODS: In this multicenter prospective observational study, pregnant women with HBV DNA levels higher than 200 000 IU/mL who received TAF or tenofovir disoproxil fumarate (TDF) from gestational weeks 24-35 to delivery were 1:1 enrolled and followed until postpartum month 6. Infants received immunoprophylaxis. The primary endpoint was the safety of mothers and infants. The secondary endpoint was the hepatitis B surface antigen (HBsAg)-positive rate at 7 months for infants. RESULTS: In total, 116 and 116 mothers were enrolled, and 117 and 116 infants were born, in the TAF and TDF groups, respectively. TAF was well tolerated during a mean treatment duration of 11.0 weeks. The most common maternal adverse event was nausea (19.0%). One (0.9%), 3 (2.6%), and 9 (7.8%) mothers had abnormal alanine aminotransferase levels at delivery and at postpartum months 3 and 6, respectively. The TDF group had safety profiles that were comparable to those of the TAF group. No infants had birth defects in either group. The infants' physical and neurological development at birth and at 7 months in the TAF group were comparable with those in the TDF group. The HBsAg positive rate was 0% at 7 months in all 233 infants. CONCLUSIONS: Antiviral prophylaxis with TAF was determined to be generally safe for both mothers and infants and reduced the MTCT rate to 0%.
引用
- Zeng QL, Yu ZJ, Ji F, et al. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. Clin Infect Dis. 2021. PMID: 33395488. doi:10.1093/cid/ciaa1939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。